Probenecid reduces serum uric acid concentrations by enhancing uric acid excretion into the urine by competitively inhibiting urate reabsorption at the proximal renal tubules. Probenecid competitively inhibits tubular secretion of weak organic acids including the penicillins, some cephalosporins (not ceftriaxone, ceftazidime, or cefoperazone), sulbactam and tazobactam (not clavulanic acid), oseltamivir, etc.
Procainamide potentially may be useful for the treatment of ventricular premature complexes (VPC’s), ventricular tachycardia, or supraventricular tachycardia associated with Wolff-ParkinsonWhite (WPW) syndrome with wide QRS complexes. Higher doses may be beneficial in the treatment of supraventricular tachycardias, although procainamide cannot be considered a first-line agent for this dysrhythmia.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
確認精確物種與爬蟲或鳥類的分類群，不得將 note 當作物種 確認診斷、尿酸生成或排泄病理、腎功能與尿酸鹽結晶狀態 確認單方或複方產品、有效成分、強度、劑型與實際用途 區分治療、藥動學 boosting、機轉研究、健康動物與患病動物 確認途徑、暴露量、時程、合併藥、後果、嚴重度、處置與法域
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
90%
90-120 minutes